Rubo Cao

591 total citations
25 papers, 480 citations indexed

About

Rubo Cao is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Rubo Cao has authored 25 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Rubo Cao's work include RNA modifications and cancer (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Rubo Cao is often cited by papers focused on RNA modifications and cancer (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Rubo Cao collaborates with scholars based in China and United States. Rubo Cao's co-authors include Jie Xiong, Weiyong Zhao, Ke Yang, Pindong Li, Li Liu, Qian Ding, Qifan Yang, Jinyan Liang, Yulan Zeng and Yuting Liu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and FEBS Letters.

In The Last Decade

Rubo Cao

23 papers receiving 476 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rubo Cao China 9 298 248 135 86 53 25 480
Li-Ru He China 14 422 1.4× 189 0.8× 170 1.3× 36 0.4× 94 1.8× 19 591
Jiaping Peng China 9 248 0.8× 185 0.7× 106 0.8× 35 0.4× 48 0.9× 19 392
Shunli Peng China 9 234 0.8× 168 0.7× 194 1.4× 76 0.9× 139 2.6× 14 451
Qiliang Peng China 13 260 0.9× 268 1.1× 126 0.9× 30 0.3× 93 1.8× 43 466
Pan Tong United States 4 214 0.7× 149 0.6× 259 1.9× 106 1.2× 102 1.9× 6 449
Yuqing Ma China 11 324 1.1× 264 1.1× 87 0.6× 26 0.3× 65 1.2× 25 456
Jin‐Ling Duan China 13 265 0.9× 139 0.6× 105 0.8× 52 0.6× 93 1.8× 29 407
Ning Ning China 8 264 0.9× 266 1.1× 138 1.0× 39 0.5× 43 0.8× 12 432
Shanqi Xu China 10 218 0.7× 189 0.8× 242 1.8× 34 0.4× 103 1.9× 16 460

Countries citing papers authored by Rubo Cao

Since Specialization
Citations

This map shows the geographic impact of Rubo Cao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rubo Cao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rubo Cao more than expected).

Fields of papers citing papers by Rubo Cao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rubo Cao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rubo Cao. The network helps show where Rubo Cao may publish in the future.

Co-authorship network of co-authors of Rubo Cao

This figure shows the co-authorship network connecting the top 25 collaborators of Rubo Cao. A scholar is included among the top collaborators of Rubo Cao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rubo Cao. Rubo Cao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ye, Ting, et al.. (2025). Phase I Trial of Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Advanced Soft Tissue Sarcoma. Drug Design Development and Therapy. Volume 19. 6817–6827.
2.
Zhang, Wenxuan, et al.. (2024). Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies. Frontiers in Endocrinology. 15. 1345203–1345203. 4 indexed citations
3.
Wang, Bi‐Cheng, et al.. (2024). Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies. Frontiers in Endocrinology. 15. 1385747–1385747. 3 indexed citations
4.
5.
Shao, Qing, et al.. (2020). CPA4 Promotes EMT in Pancreatic Cancer via Stimulating PI3K-AKT-mTOR Signaling. SHILAP Revista de lepidopterología. 3 indexed citations
6.
Guo, Yubiao, et al.. (2019). Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología.
7.
Liu, Yuting, Jingjing Wu, Kai Zhang, et al.. (2019). Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer. Translational Cancer Research. 8(6). 2371–2379. 1 indexed citations
8.
Yang, Qifan, Jingsong Yang, Rubo Cao, et al.. (2019). Characteristics and prognostic significance of profiling the peripheral blood T‐cell receptor repertoire in patients with advanced lung cancer. International Journal of Cancer. 145(5). 1423–1431. 91 indexed citations
9.
Wang, Bi‐Cheng, Rubo Cao, Pindong Li, & Chen Fu. (2019). The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis. Cancer Medicine. 8(13). 5969–5978. 24 indexed citations
10.
Liu, Yuting, Jingjing Wu, Kai Zhang, et al.. (2019). Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer. Translational Cancer Research. 8(6). 2371–2379. 8 indexed citations
11.
Wang, Bi‐Cheng, Fan Tong, Jinsong Yang, et al.. (2018). Application of dynamic monitoring of genomic profiles in non-small cell lung cancer. Medicine. 97(51). e13192–e13192. 1 indexed citations
12.
Peng, Gang, Rubo Cao, Jun Xue, et al.. (2014). Increased expression of SHP-1 is associated with local recurrence after radiotherapy in patients with nasopharyngeal carcinoma. Radiology and Oncology. 48(1). 40–49. 8 indexed citations
13.
Peng, Gang, et al.. (2014). Alterations of cell cycle control proteins SHP-1/2, p16, CDK4 and cyclin D1 in radioresistant nasopharyngeal carcinoma cells. Molecular Medicine Reports. 10(4). 1709–1716. 25 indexed citations
14.
Yang, Ke, Weiyong Zhao, Jie Xiong, & Rubo Cao. (2013). Downregulation of miR‐16 promotes growth and motility by targeting HDGF in non‐small cell lung cancer cells. FEBS Letters. 587(18). 3153–3157. 83 indexed citations
15.
Cao, Rubo, Qian Ding, Pindong Li, et al.. (2013). SHP1-mediated cell cycle redistribution inhibits radiosensitivity of non-small cell lung cancer. Radiation Oncology. 8(1). 178–178. 19 indexed citations
16.
Yang, Ke, Weiyong Zhao, Jie Xiong, & Rubo Cao. (2013). miR-149 Inhibits Non-Small-Cell Lung Cancer Cells EMT by Targeting FOXM1. Biochemistry Research International. 2013. 1–8. 127 indexed citations
17.
Cao, Rubo, et al.. (2011). Raltitrexed versus fluorouracil/leucovorin combined with oxaliplatin for advanced colorectal cancer: a prospective study. 34(4). 7–10. 1 indexed citations
18.
Peng, Gang, et al.. (2010). The invasive malignancy from peritoneal epithelial cell: a report of four cases and review of literature. Medical Oncology. 28(2). 597–600. 1 indexed citations
19.
Dong, Xiaorong, Jing Huang, Rubo Cao, & Li Liu. (2010). Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. Medical Oncology. 28(4). 1425–1429. 16 indexed citations
20.
Cao, Rubo. (2006). CD4~+CD25~(high) regulatory cells in peripheral blood of cancer patients. Zhonghua jianyan yixue zazhi. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li-Ru He Breakdown of academic impact, for papers by Jiaping Peng Breakdown of academic impact, for papers by Shunli Peng Breakdown of academic impact, for papers by Qiliang Peng Breakdown of academic impact, for papers by Pan Tong Breakdown of academic impact, for papers by Yuqing Ma Breakdown of academic impact, for papers by Jin‐Ling Duan Breakdown of academic impact, for papers by Ning Ning Breakdown of academic impact, for papers by Shanqi Xu
Rankless by CCL
2026